By Dr. Jade Stefano
Alzheimer’s disease is one of the most devastating neurodegenerative conditions, affecting millions of people worldwide. Diagnosing Alzheimer’s early is crucial for managing symptoms and planning for the future, but traditional diagnostic methods often involve invasive and expensive procedures. The PrecivityAD2™ test, a revolutionary blood test, offers a non-invasive, accessible, and highly accurate alternative for detecting brain amyloid pathology, a key hallmark of Alzheimer’s disease.[1]
Availability and Financial Assistance
The PrecivityAD2™ test is available at AIMS Institute, providing patients with a non-invasive option for Alzheimer’s disease detection. Additionally, financial assistance based on income is available through C2N Diagnostics. More information the test and on financial assistance can be found at: https://precivityad.com
Understanding Alzheimer’s Disease Diagnosis
Alzheimer’s disease is characterized by the accumulation of amyloid plaques and neurofibrillary tangles in the brain. Traditionally, diagnosing Alzheimer’s has relied on:
- Cognitive assessments to evaluate memory and reasoning abilities.
- Positron emission tomography (PET) scans, which detect amyloid buildup but are costly and require specialized imaging facilities.
- Cerebrospinal fluid (CSF) analysis, which involves a lumbar puncture (spinal tap), an invasive and sometimes uncomfortable procedure.
While these methods are effective, they come with drawbacks, including accessibility issues, cost, and patient discomfort. The PrecivityAD2™ test changes this landscape by offering a simple blood test that delivers highly reliable results.[1]
What is the PrecivityAD2™ Test?
The PrecivityAD2™ test is a high-throughput, mass spectrometry-based blood test designed to identify the presence of amyloid pathology in the brain. It works by measuring two key biomarkers in the blood:
- Phosphorylated tau at threonine 217 (%p-tau217)
- The amyloid beta (Aβ)42/40 ratio
These biomarkers have been strongly associated with Alzheimer’s disease pathology. The test combines these measurements using a sophisticated algorithm to generate an Amyloid Probability Score 2 (APS2). This score correlates with brain amyloidosis, which has been confirmed through amyloid PET imaging.[1]
How Accurate is the PrecivityAD2™ Test?
Clinical validation studies have demonstrated that the PrecivityAD2™ test has a high diagnostic performance:
- It achieved an area under the receiver operating characteristic curve (AUC-ROC) of 0.94, which is considered excellent.[1]
- The test results showed an 88% agreement with amyloid PET imaging, confirming its reliability.[1]
- The accuracy was consistent across different ethnicities, sexes, ages, and ApoE4 statuses (a genetic risk factor for Alzheimer’s disease).[1]
These results indicate that the PrecivityAD2™ test is comparable in accuracy to PET scans and cerebrospinal fluid tests but with greater accessibility and ease of use.[1]
Comparing PrecivityAD2™ to Other Diagnostic Methods
1. PET Scans
- Accuracy: PET scans are the gold standard for detecting amyloid plaques, but the PrecivityAD2™ test achieves similar accuracy.[1]
- Invasiveness: PET scans require the injection of a radioactive tracer and specialized imaging, whereas PrecivityAD2™ only requires a simple blood draw.
- Cost and Accessibility: PET scans are expensive and may not be available in all medical centers. In contrast, PrecivityAD2™ is a more affordable and widely accessible option.[2]
2. Cerebrospinal Fluid (CSF) Biomarkers
- Accuracy: CSF biomarkers provide high accuracy for detecting Alzheimer’s, but PrecivityAD2™ is comparable in diagnostic performance.[1]
- Invasiveness: CSF tests require a lumbar puncture, which some patients find uncomfortable or risky, whereas PrecivityAD2™ is completely non-invasive.
- Practicality: Many patients are hesitant to undergo a spinal tap, making a blood test a more attractive option.
3. Other Blood-Based Biomarkers
Several blood tests measuring tau and amyloid biomarkers have been developed, but PrecivityAD2™ stands out due to its:
- High accuracy, with an AUC-ROC of 0.94[1]
- Reliability across diverse populations[1]
- Ease of implementation in clinical settings[2]
Why Early Detection Matters
Detecting Alzheimer’s disease early provides numerous benefits, including:
- Early intervention with lifestyle changes or medications that may slow disease progression.
- Participation in clinical trials, offering access to promising new treatments.[2]
- Better planning for future care and decision-making for patients and families.
With PrecivityAD2™, early detection becomes more feasible than ever, empowering healthcare providers to diagnose and manage Alzheimer’s more effectively.[2]
Who Should Consider the PrecivityAD2™ Test?
The PrecivityAD2™ test is ideal for:
- Individuals experiencing memory loss or cognitive decline.
- Patients with a family history of Alzheimer’s disease.
- People at risk of Alzheimer’s due to age or genetic factors.
- Clinicians seeking a non-invasive diagnostic tool before recommending PET scans or lumbar punctures.
What’s Next for Alzheimer’s Diagnostics?
The PrecivityAD2™ test represents a major step forward in Alzheimer’s diagnostics, making early detection more accessible and reliable.[1] As research progresses, we can expect further advancements in blood-based biomarkers, potentially leading to even earlier and more precise detection methods.[2]
For patients and families facing the uncertainty of cognitive decline, having a simple, accurate, and non-invasive option like PrecivityAD2™ is a game-changer. By embracing this new technology, the medical community can improve Alzheimer’s care and offer hope for the future.
References:
- Meyer MR, Kirmess KM, Eastwood S, et al. Clinical Validation of the PrecivityAD2™ Blood Test: A Mass Spectrometry-Based Test With Algorithm Combining %P-Tau217 and Aβ42/40 Ratio to Identify Presence of Brain Amyloid. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association. 2024;20(5):3179-3192. doi:10.1002/alz.13764.
- Palmqvist S, Tideman P, Mattsson-Carlgren N, et al. Blood Biomarkers to Detect Alzheimer’s Disease in Primary Care and Secondary Care. JAMA. 2024;332(15):1245-1257. doi:10.1001/jama.2024.13855.
